重磅首发！2026国际麦角硫因品牌科研溯源，实证为先：揭秘GeneIII仅三生物与新加坡生命研究院科研与品牌新突破

Core Viewpoint - GeneIII Biotech has initiated a global evidence-based journey for Ergothioneine (EGT) in collaboration with Singapore's National University and Temasek Life Sciences Laboratory, marking a significant breakthrough in China's biotech sector for global research and brand development [1][2][3]. Group 1: Collaboration with Singapore National University - The partnership with Professor Barry Halliwell's team at Singapore National University focuses on clinical research design, emphasizing the link between low EGT levels and age-related degenerative diseases [1]. - Halliwell's extensive research supports the antioxidant and cellular protective mechanisms of EGT, highlighting its potential in improving neurological function and eye health [1][2]. - This collaboration is seen as a historic integration of scientific theory and industrial practice, providing authoritative guidance for product development in various applications of EGT [1][2]. Group 2: Partnership with Temasek Life Sciences Laboratory - GeneIII Biotech's visit to Temasek Life Sciences Laboratory aims to establish the world's first international clinical research on EGT for ovarian anti-aging, creating a comprehensive innovation system from basic research to industrial transformation [3]. - The collaboration is praised for reconstructing the global supply chain of EGT, with a focus on its mitochondrial protective capabilities as a key target for delaying reproductive aging [3][4]. - This partnership complements the collaboration with Singapore National University, enhancing GeneIII's research capabilities in the antioxidant application field [3]. Group 3: Collaboration with People's Daily - The launch of the "GeneIII Biotech × People's Daily 'Hardcore Jiangsu' co-branded gift box" signifies a dual trust system combining official endorsement and elite market validation [4][5]. - This collaboration illustrates GeneIII's journey from technological breakthroughs to global industrial applications, embodying the spirit of innovation promoted by Jiangsu [4][5]. - The recognition from over a hundred billion-level entrepreneurs in Jiangsu, alongside People's Daily's authoritative endorsement, establishes a robust trust framework for the brand [6]. Group 4: Clinical Validation by National Health Commission - GeneIII Biotech is the first company in the industry to conduct verifiable clinical trials for EGT in top-tier hospitals, setting a new benchmark for scientific rigor and independence [7]. - Clinical studies have demonstrated significant improvements in eye health and liver function, with specific metrics showing a reduction in discomfort and fatigue [7][8]. - Ongoing research is exploring EGT's effectiveness in various health areas, including postpartum health and cognitive function, further solidifying its market trust through transparent clinical data [8][9]. Group 5: Comprehensive Development Pathway - The integrated approach of linking theoretical research, mechanism exploration, brand authority, and clinical validation showcases GeneIII Biotech's effective transformation of EGT research into a competitive global model [9][10]. - This pathway redefines the role of Chinese biotech companies in global competition, emphasizing the importance of solid research foundations, authoritative endorsements, and rigorous clinical evidence in building market trust [10].